GlassScriptPhysician profile
Hazel Rose King
NPI 1558905356
$1,532.01
in general payments reported to CMS, 2019-2025
23 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $85.55 · 2022: $122 · 2023: $545 · 2024: $419 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,324.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $242.58 | 2023 | Ingrezza |
| Nalu Medical, INC. | $241.84 | 2023 | Nalu Neurostimulation System |
| Abbvie INC. | $210.21 | 2024-2025 | |
| Avanir Pharmaceuticals, INC. | $85.55 | 2021 | |
| Urovant Sciences INC | $82.03 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $80.75 | 2024-2025 | Airsupra, Breztri |
| Mayne Pharma Commercial LLC | $78.22 | 2024-2025 | |
| Novo Nordisk INC | $70.64 | 2024-2025 | Rybelsus, Ozempic |
| Corcept Therapeutics | $56.56 | 2024-2025 | Korlym |
| Sumitomo Pharma America, INC. | $43.91 | 2024-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $40.36 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.73 | 2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $36.24 | 2024 | Spravato |
| Pfizer INC. | $35.02 | 2024 | |
| Hologic Sales and Service, LLC | $30.59 | 2025 | Aptima |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $25.86 | 2023 | |
| Phadia US INC. | $23.69 | 2024 | Immunocap |
| Dexcom, INC. | $20.00 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $19.94 | 2025 | Prolia, Evenity |
| Shield Therapeutics INC | $19.83 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $19.55 | 2023 | Rexulti |
| Lilly USA, LLC | $15.10 | 2023 | Trulicity |
| Viatris Specialty LLC | $13.81 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hazel King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.